Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLERA sequential rituximab/abatacept trial in ACPA-positive rheumatoid arthritis
2018-003877-91Phase 2Completed
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab and abatacept in rheumatoid arthritis (RA) (2 arms), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Proportion of anti-CCP2 antibody seroconversions at week 52. Started Feb 2019; status: completed.
02
Drugs
rituximababatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-003877-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003877-91.